{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-005373","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2021-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.923288+00:00","generated_at":"2026-06-29T23:57:59.308888+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corvus Q2 net loss $11.8M; discontinues COVID-19 trial, cuts cash burn guidance","bullets":["Cash, equivalents and marketable securities $66.5M at June 30, 2021, up from $44.3M at Dec 31, 2020.","Net loss $11.8M for Q2 2021 vs $10.6M in Q2 2020; R&D expenses $9.1M (up $1.2M YoY).","Discontinued Phase 3 mupadolimab COVID-19 trial in July 2021 (no safety/efficacy issue); full-year cash burn guidance cut ~$11M to $35-37M.","Enrolling Phase 1b/2 trial of mupadolimab plus pembrolizumab in HPV+ oropharyngeal cancer; results expected by year-end 2021.","Angel Pharmaceuticals filed IND in China for CPI-818 Phase 2 in T-cell lymphomas; ciforadenant Phase 2 RCC trial planned with Kidney Cancer Consortium."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-005373","json":"https://secwatch.observer/filing/0001171843-21-005373.json","markdown":"https://secwatch.observer/filing/0001171843-21-005373.md","text":"https://secwatch.observer/filing/0001171843-21-005373.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/0001171843-21-005373-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184321005373/f8k_080221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T23:57:59.308888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}